Triple Therapy for Severe Asthma - More Than the Sum of its Parts
Severe asthma remains a major clinical challenge despite advances in inhaled therapies, biologics, and personalized medicine. Many patients continue to experience persistent symptoms, frequent exacerbations, impaired lung function, and reduced quality of life even while receiving standard treatment. Triple therapy, which combines an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), has emerged as an important treatment strategy for selected patients with uncontrolled severe asthma. This approach targets multiple inflammatory and bronchoconstrictive pathways simultaneously, making it “more than the sum of its parts.”
Learning Outcomes
What you'll learn
- Describe the most recent asthma guidelines (AIR-MART regimens) for the use of ICS-formoterol in cases of mild, moderate, and severe asthma.
- Describe a strategy for treating acute asthma symptoms with ICS-formoterol, including the use of smaller devices like DPI.
- Enumerate the resources that clinicians and patients can use to help implement an ICS-formoterol asthma treatment regimen.
- Remember that the hydrofluorocarbon propellants used in pMDI are strong greenhouse gases; newer propellants are being developed, and other devices are available.
- Describe a strategy for giving patients the choice to switch from pMDIs to an efficient and evidence-based ICS-formoterol regimen via DPI.
Learning Outcomes
What you'll learn
- Describe the most recent asthma guidelines (AIR-MART regimens) for the use of ICS-formoterol in cases of mild, moderate, and severe asthma.
- Describe a strategy for treating acute asthma symptoms with ICS-formoterol, including the use of smaller devices like DPI.
- Enumerate the resources that clinicians and patients can use to help implement an ICS-formoterol asthma treatment regimen.
- Remember that the hydrofluorocarbon propellants used in pMDI are strong greenhouse gases; newer propellants are being developed, and other devices are available.
- Describe a strategy for giving patients the choice to switch from pMDIs to an efficient and evidence-based ICS-formoterol regimen via DPI.
Modules
Module 1
Latest Asthma Guidelines for ICS-Formoterol in Mild, Moderate, and Severe Asthma
Module 2
Treating Acute Asthma Symptoms with ICS-Formoterol Including DPI Use
Module 3
Resources for Implementing an ICS-Formoterol Regimen
Module 4
Environmental Impact of pMDIs and Newer Device Options
Module 5
Helping Patients Switch from pMDIs to ICS-Formoterol DPI by Choice
Module 6
Summary
.jpg)
.jpg)
.jpg)
.jpg)
Top reviews
No reviews yet.
You May Also Like
.jpg)
.jpg)
.jpg)
.jpg)
Learn Anytime
Anywhere
Experience the next level of learning with the Care Learning app. Available on Android and iOS.
Come and Work
with Us!
Join us as a healthcare trainer providing practical sessions to professionals and workers.
Apply for Trainer RoleIn-Person Practical
Healthcare Training
Enroll in our accredited, hands-on practical training sessions to deliver better patientcentred care.
Apply for TrainingRefer &
Earn Rewards.
Invite healthcare professionals to join Care Learning and earn rewards for every successful referral.
Frequently Asked Questions
Triple therapy refers to the combination of ICS, LABA, and LAMA to improve asthma control when dual therapy is insufficient.
Patients with persistent symptoms or frequent exacerbations despite optimized ICS/LABA therapy may be considered.
No. Triple therapy uses inhaled medications, while biologics are injectable targeted therapies for selected phenotypes.
Yes. In appropriate patients, it may lower exacerbation frequency and improve lung function.
Possible effects include dry mouth, tremor, throat irritation, or hoarseness depending on the medication components.
It may improve convenience and adherence, though suitability depends on patient preference and availability.